Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team
03 juin 2021 16h01 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...
Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer
01 juin 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences to Present at Upcoming Investor Conferences in June
26 mai 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting
13 mai 2021 07h00 HE
|
Evelo Biosciences, Inc.
–On-track to initiate clinical development of EDP2939 in 2022– CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company...
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
29 avr. 2021 07h00 HE
|
Evelo Biosciences, Inc.
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief...
Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
22 avr. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
20 avr. 2021 16h01 HE
|
Evelo Biosciences, Inc.
–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting– –Meaningful improvements over placebo on clinical scores, including new data released on key...
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
15 avr. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
05 avr. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
23 mars 2021 03h00 HE
|
Evelo Biosciences, Inc.
-- Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in...